Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, ...
Abbott aims to roll out its continuous glucose monitor that also tracks ketone levels for diabetic ketoacidosis by the end of the year.
Abbott Laboratories remains a "Buy," anticipating double-digit growth, despite near-term volatility and underwhelming 2026 ...
Abbott Laboratories (NYSE:ABT) is one of the top 10 picks in President Trump’s latest stock portfolio. Trump bought $1 ...
The Texas Tribune on MSN
Texas Latinos are turning on Trump. That doesn’t mean they’re sold on Democrats.
Latino strategists and voters say this year’s swing is driven by anger at those in power and hinges on individual candidates.
Abbott Laboratories will separate its nutrition business into an independent, publicly traded company via a tax-free spin-off by the end of 2027, ...
Abbott Laboratories reported net sales of $13,013 million for the third quarter ended Sept. 30, 2026, representing a 14.5 percent increase on a reported basis and 7.0 percent on a comparable basis ...
More than 30 million Americans live with Type 2 diabetes, and for many, managing it feels like a guessing game. Many also ...
Abbott reports Q3 2026 revenue of $13.01 billion and adjusted EPS of $1.42, alongside plans to spin off its Nutrition ...
The planned separation of Nutrition comes as Abbott reports $13 billion in third-quarter sales and narrows its 2026 earnings outlook.
Zacks Investment Research on MSN
Dexcom's G7 shows strong results in type 2 diabetes CONNECT study
DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...
Abbott on Oct. 21, 2026, reported third-quarter net sales of $13.013 billion (U.S.), up 14.5 percent on a reported basis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results